Cheson Bruce D
Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, 20007, USA,
Curr Oncol Rep. 2015 Jun;17(6):27. doi: 10.1007/s11912-015-0452-2.
Standardized response criteria for lymphoma are critical for the evaluation of new therapies. Widely adopted recommendations, most recently the Lugano classification, have been developed primarily for assessment of conventional chemotherapeutic regimens. More recently, several classes of drugs, including immunomodulatory agents, B cell receptor pathway targeting kinases, and checkpoint (PD-1, PDL-1) inhibitors have demonstrated impressive activity in a broad range of histologies. However, they may be associated with features during treatment suggestive of progressive disease despite clinical benefit. Immune response criteria have been proposed for solid tumors, and a modification is needed to be more applicable to lymphomas. Following treatment, conservative use of imaging is recommended based on clinical indications. As newer targeted agents with unique mechanisms of action are developed, current response and follow-up criteria must be made sufficiently flexible for optimal evaluation.
淋巴瘤的标准化反应标准对于评估新疗法至关重要。广泛采用的建议，最近是卢加诺分类，主要是为评估传统化疗方案而制定的。最近，几类药物，包括免疫调节剂、B细胞受体途径靶向激酶和检查点（PD-1、PDL-1）抑制剂，已在广泛的组织学类型中显示出令人印象深刻的活性。然而，尽管有临床获益，但它们在治疗期间可能与提示疾病进展的特征相关。已经针对实体瘤提出了免疫反应标准，需要进行修改以更适用于淋巴瘤。治疗后，建议根据临床指征保守使用影像学检查。随着具有独特作用机制的新型靶向药物的开发，当前的反应和随访标准必须足够灵活以进行最佳评估。
